A New Jersey federal judge on Tuesday agreed to postpone class certification hearings in antitrust multidistrict litigation over cholesterol medication Lipitor after Ranbaxy Laboratories Ltd. told the court an unidentified attorney is "currently trapped in the war zone in Israel with no foreseeable way to get out."
A closeup of a white drug bottle with a label that says Lipitor (atorvastatin calcium) outlined in red above a red box that says 20 mg in white text.
The attorney in Israel is defending the class certification bid by consumers and health benefit plans, or end payers, who allege Ranbaxy's patent dispute settlement with Pfizer Inc. delayed the entrance of lower-priced generics into the market. (AP Photo/Mark Lennihan, file)
U.S. District Judge Peter G. Sheridan rescheduled Oct. 16 and Oct. 17 hearings to Oct. 26 and Oct. 27 following the Monday postponement bid by Ranbaxy, which not identify the counsel in its letter to the court.
. . .
The end payor plaintiffs are represented by Lisa Rodriguez of Schnader Harrison Segal & Lewis LLP, Sharon Robertson of Cohen Milstein Sellers & Toll PLLC, Kenneth A. Wexler of Wexler Boley & Elgersma LLP, Michael Buchman of Motley Rice LLC and Chad Holtzman of Grant & Eisenhofer PA.